Drug Database
FL

fluticasone propionate

✓ Approved

Cantabria Labs · NR3C1 · Small Molecule

What is fluticasone propionate?

fluticasone propionate is a small molecule developed by Cantabria Labs. It is approved for therapeutic indications via topical.

Drug Profile

CompanyCantabria Labs
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Cantabria Labs

Mechanism of Action

Molecular Targets

fluticasone propionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

fluticasone propionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
InvestigationsDermatologic examination✓ Approved

Related Research Articles

PubMedDEN open2026-07-17

Lymphocytic Esophagitis Mimicking Eosinophilic Esophagitis and Esophageal Candidiasis: A Case Report.

Sugawara Hiroshi H, Eizuka Makoto M, Toya Yosuke Y, Sugimoto Ryo R et al.

A 59-year-old man presented with a 5-year history of progressive dysphagia. Esophagogastroduodenoscopy (EGD) revealed an esophageal stricture with adherent whitish exudates, and biopsy specimens demonstrated fungal elements. Subsequent EGD showed longitudinal furrows, concentric rings, and white exudates, mimicking eosinophilic esophagitis. Biopsy specimens revealed marked intraepithelial lymphocytic infiltration without eosinophils. Immunohistochemistry demonstrated a predominance of CD3-positive T cells, leading to a diagnosis of lymphocytic esophagitis. Despite treatment with proton pump inhibitors, H2-receptor antagonists, antifungal agents, and inhaled fluticasone, his symptoms persisted without sustained improvement.

PMID 42465714
Read full article →
PubMedbioRxiv : the preprint server for biology2026-07-17

Allosteric Gating Mechanism Regulates Odorant Selectivity and Antagonism in Odorant Receptors.

Ma Ning N, Marie Mona M, Takase Dan D, Del Torrent Masachs Clàudia Llinàs CL et al.

Odorant receptors (ORs) belong to class A G protein coupled receptors that detect diverse small molecules, yet the steps that link odorant association to receptor mediated selectivity remains incompletely defined. Here we combined 1.26 milliseconds of all-atom odorant association Molecular Dynamics simulations with Markov state modeling and cell-based cAMP measurements to examine two human ORs receptors that recognize chemically distinct odorants. In the class I receptor OR51E2, propionate associates via two extracellular pathways gated for selectivity by residues in the extracellular loop 2 and 3. The longer alkyl chain heptanoate occupies this gate and reduces propionate association and signaling which is consistent with the observed antagonist behavior of heptanoate. Pocket-expanding mutations at F155 and L158 allosterically regulate ECL2-ECL3 gate by permitting longer-chain fatty acids to adopt fully inserted poses that support gate closure, while also attenuating propionate responses. In the class II receptor OR1A1, hydrophobic odorants partition into the membrane and reach the orthosteric site mostly through multiple transmembrane paths. A mutational scan of gating residues and analysis of intermediate-state occupancies suggest that an orthosteric substitution at G108 can allosterically bias odorant association path choice. Together, these results support a model in which odorant association paths and gate residence, together with allosteric coupling between the orthosteric site and entry gates, contribute to odorant specificity and antagonism in odorant receptors.

PMID 42465389
Read full article →
PubMedActa ophthalmologica2026-07-17

Efficacy and safety of topical macrolides versus systemic tetracyclines for meibomian gland dysfunction-a systematic review and meta-analysis.

Safir Margarita M, Chan Clara C CC, Teichman Joshua C JC, Arbel Itamar I et al.

To review the efficacy and safety of oral doxycycline antibiotics versus topical macrolides in the treatment of meibomian gland dysfunction (MGD). Systematic review and meta-analysis. A comprehensive search of PubMed, Scopus, Embase, and ClinicalTrials.gov through December 2024 identified randomised controlled trials (RCTs) comparing oral tetracyclines with topical macrolides for MGD. Eligible studies reported outcomes related to tear film stability, meibomian gland function, ocular surface health, or symptom severity. Data extraction followed PRISMA guidelines and risk of bias was assessed using Cochrane methods. Among 3699 publications (1964-2024), six RCTs from distinct locations (374 patients) met inclusion criteria, describing only topical azithromycin and oral doxycycline. Treatment regimens were comparable: one month of topical azithromycin (1-1.5%, once to four times daily) versus three to 8 weeks of oral doxycycline (100-200 mg daily). Both treatments significantly improved MGD signs and symptoms. In pooled analyses, topical azithromycin showed superiority in reducing tear debris (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.15-0.74); however, while the total symptoms score favoured azithromycin, the result was borderline (OR, 0.62; 95% CI, 0.38-1.00) and sensitivity-dependent. Subgroup analysis showed doxycycline was superior for corneal fluorescein staining (standardised mean difference [SMD], 0.64; 95% CI, 0.22-1.05), whereas 1% azithromycin was superior for tear breakup time (mean difference [MD], -1.40; 95% CI, -2.20 to -0.60) and dropout-causing adverse events (risk ratio [RR], 0.07; 95% CI, 0.01-0.49). Both topical azithromycin and oral doxycycline are effective for MGD management. Topical azithromycin demonstrated a more favourable safety profile and may represent a useful therapeutic option, particularly for patients with low tolerance to systemic medications. However, further high-quality studies are needed to strengthen the evidence base.

PMID 42464955
Read full article →
PubMedFrontiers in pediatrics2026-07-17

Case Report: Successful topical simvastatin therapy in a 2-year-old girl with keratin 16-associated palmoplantar epidermal differentiation disorder.

Zhong Qingmei Q, Zhang Ying Y, Feng Zhen Z, Zhang Jinyan J et al.

Palmoplantar epidermal differentiation disorder associated with pachyonychia congenita is a rare autosomal dominant genodermatosis characterized by painful palmoplantar hyperkeratosis and nail dystrophy. Treatment options remain limited, particularly in young children, in whom systemic therapies carry safety concerns. Herein, we report a 2-year-old girl who presented with palmoplantar hyperkeratosis since 1 month of age, with progressive nail dystrophy involving all 20 nails. Whole-exome sequencing identified a hemizygous multi-exon deletion in keratin 16 (ClinVar: SUB16259296; OMIM: #167200), and orthogonal validation using amplicon-based high-throughput sequencing confirmed a 437-nucleotide deletion predicted to result in a frameshift with premature termination codon (PTC). American College of Medical Genetics and Genomics classification supported likely pathogenicity. Twice-daily application of topical 2.5% simvastatin/cholesterol cream for 11 weeks produced substantial improvement in plantar hyperkeratosis, resolution of painful fissures, and visibly improved morphology of nascent nail growth. No local or systemic adverse effects were observed. This case provides preliminary evidence that topical simvastatin may be an effective and well-tolerated therapy for keratin 16-associated palmoplantar epidermal differentiation disorder in young children, and highlights the potential importance of topical drug delivery in achieving therapeutic efficacy for this genetic subtype.

PMID 42465212
Read full article →
PubMedThe international journal of lower extremity wounds2026-07-17

Comparison of Topical Rifamycin and a Chlorhexidine-Containing Wound Dressing in Infected and Non-Infected Experimental Wound Models.

Türker Kadir Yağız KY, Odabaş Irem Saadet IS, Evirgen Oya O, Yurtçu Ebru Evren EE et al.

AimTo compare topical rifamycin versus a chlorhexidine-containing wound dressing for wound healing and microbial load in infected and non-infected wound models.MethodsThirty rats were studied in two stages across five groups (n = 6). Full-thickness 1 × 2 cm interscapular wounds were created. Group 1 received saline irrigation (control), Group 2 topical rifamycin, Group 3 chlorhexidine-containing dressing (CHD), Group 4 infection with Staphylococcus aureus ATCC 25923 followed by rifamycin, and Group 5 the same infection followed by CHD. Animals were housed individually. On day 7, rats were sacrificed and wounds excised; specimens were divided equally for microbiology and histology.ResultsOn day-7 histology, the control group had the lowest wound healing score (7.66 ± 0.82). The highest score occurred in the CHD group (11.33 ± 1.75), followed by the rifamycin group (10.5 ± 0.55). No significant differences were found between non-infected groups (p = 0.292) or infected groups (p = 0.360). In infected groups, the CHD group showed lower total bacterial colony counts and fewer colonies per milligram of tissue, but differences were not significant (p = 0.091, p = 0.200).ConclusionCHD tended to outperform rifamycin in wound healing and limiting bacterial growth, but no significant difference was detected. This study informs clinical use of both products.

PMID 42464477
Read full article →
PubMedCureus2026-07-17

Comparative Evaluation of Calendula officinalis and Povidone-Iodine in Facial Wound Healing.

Hammannavar Reshma R, Patil Harshal H, Berad Uday D UD, Borse Ashlesha P AP et al.

Facial wound healing is an important aspect of postoperative care in oral and maxillofacial surgery, because optimal healing is essential for both functional and esthetic outcomes. Topical agents with antimicrobial and anti-inflammatory properties are routinely used to enhance wound healing and to prevent postoperative complications. This study aimed to evaluate and compare the effectiveness of Calendula officinalis tincture and povidone-iodine ointment in the management of facial wounds. This study aimed to compare wound-healing outcomes between the two groups using the Early Wound Healing Score (EHS), evaluate the efficacy of Calendula officinalis tincture in promoting wound healing, assess the efficacy of povidone-iodine ointment in postoperative wound care, compare the incidence of wound infection or dehiscence between the groups, and evaluate patient satisfaction following topical wound management. The primary outcome of this study was the total Early Wound Healing Score (EHS) at day 14, while key secondary outcomes included the clinical signs of inflammation (CSI) score, wound infection rate, and patient satisfaction. This prospective observational clinical study included 64 participants with facial wounds who required postoperative wound care. Participants were divided into two observational groups based on the topical medication prescribed during routine clinical practice. Group A included 32 participants treated with Calendula officinalis tincture, while group B included 32 participants treated with povidone-iodine ointment. Wound healing was assessed using the Early Wound Healing Score (EHS), which included clinical signs of re-epithelialization, hemostasis, and inflammation at baseline and on days three, seven, and 14. Statistical analysis was performed using Mann-Whitney U test, Friedman test, and chi-square test. Statistical significance was set at p < 0.05. The mean age of participants was 31.6 ± 9.4 years in group A and 33.1 ± 10.2 years in group B. Baseline EHS scores were comparable between the groups (p > 0.05). A significant improvement in wound healing was observed in both groups throughout the follow-up period (p < 0.001). However, group A demonstrated significantly higher total EHS scores than group B from day three onwards. At day 14, the mean total EHS was 7.81 ± 0.61 in group A compared to 7.06 ± 0.87 in group B (p = 0.001). Group A also showed significantly better re-epithelialization and lower inflammation scores during follow-up evaluation. Calendula officinalis tincture and povidone-iodine ointment promote satisfactory facial wound healing. However, Calendula officinalis tincture demonstrated superior healing outcomes with improved re-epithelialization and reduced inflammation, suggesting its potential as an effective topical agent for postoperative facial wound management.

PMID 42465172
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about fluticasone propionate